Gossamer Bio, Inc. (NASDAQ:GOSS) Given Consensus Rating of “Hold” by Brokerages

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have been assigned a consensus recommendation of “Hold” from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $5.00.

Several research firms recently issued reports on GOSS. Wedbush reiterated a “neutral” rating and issued a $1.00 price target (down from $6.00) on shares of Gossamer Bio in a report on Tuesday, February 24th. Royal Bank Of Canada upgraded Gossamer Bio to an “outperform” rating in a report on Tuesday, February 24th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Gossamer Bio in a report on Monday, March 23rd. Leerink Partners cut Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, Weiss Ratings cut Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 19th.

Gossamer Bio News Roundup

Here are the key news stories impacting Gossamer Bio this week:

• Negative Sentiment: Multiple law firms, including Frank R. Cruz, Faruqi & Faruqi, Rosen, Pomerantz, Bronstein Gewirtz & Grossman, and Schall, published reminders and investor alerts about an already filed securities fraud class action against Gossamer Bio. Article: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: The lawsuits center on allegations related to the February 23, 2026 disclosure that top-line Phase 3 PROSERA results failed to meet the primary endpoint, a development that can increase uncertainty around the company’s pipeline and future value. Article: Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- HBSS
• Neutral Sentiment: Several notices highlight a June 1, 2026 lead-plaintiff deadline for investors who bought GOSS shares during the class period, adding to the near-term legal spotlight but not changing the scientific or operational outlook by itself. Article: GOSS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026

Hedge Funds Weigh In On Gossamer Bio

Several hedge funds have recently added to or reduced their stakes in GOSS. Kalehua Capital Management LLC bought a new position in Gossamer Bio in the first quarter valued at about $3,363,000. State Street Corp boosted its holdings in Gossamer Bio by 139.7% in the fourth quarter. State Street Corp now owns 9,310,969 shares of the company’s stock valued at $28,864,000 after acquiring an additional 5,427,302 shares during the last quarter. Corient Private Wealth LLC lifted its stake in Gossamer Bio by 19,123.7% in the fourth quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock valued at $11,922,000 after buying an additional 3,825,879 shares during the period. Millennium Management LLC boosted its holdings in Gossamer Bio by 629.3% during the third quarter. Millennium Management LLC now owns 3,619,329 shares of the company’s stock worth $9,519,000 after buying an additional 3,123,081 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in Gossamer Bio by 4,196.2% during the third quarter. Bank of America Corp DE now owns 2,881,904 shares of the company’s stock worth $7,579,000 after buying an additional 2,814,824 shares during the last quarter. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Stock Performance

Shares of GOSS stock opened at $0.21 on Monday. The stock’s fifty day moving average is $0.36 and its 200-day moving average is $1.75. The stock has a market capitalization of $49.31 million, a PE ratio of -0.27 and a beta of 2.15. Gossamer Bio has a 52 week low of $0.16 and a 52 week high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Monday, May 18th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The firm had revenue of $16.96 million during the quarter, compared to the consensus estimate of $4.67 million. As a group, analysts forecast that Gossamer Bio will post -0.47 earnings per share for the current fiscal year.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.